The present invention relates to a process for preparing a catalyst component for polymerization of an olefin comprising the steps of: i) contacting a compound R.sup.9.sub.zMgX.sub.2-z wherein R.sup.9 is aromatic, aliphatic or cyclo-aliphatic group containing up to 20 carbon atoms, X is a halide, and z is in a range of larger than 0 and smaller than 2, with an alkoxy- or aryloxy-containing silane compound to given a first intermediate reaction product; ii) contacting the first intermediate reaction product with at least one activating compound selected from the group formed by electron donors and compounds of formula M(OR.sup.10).sub.v-w(OR.sup.11).sub.w, wherein M can be Ti, Zr, Hf, Al or Si, and M(OR.sup.10).sub.v-w(R.sup.11).sub.w, wherein M is Si, each R.sup.10 and R.sup.11, independently, represent an alkyl, alkenyl or aryl group, v is the valency of M, v being either 3 or 4, and w is smaller than v, to give a second intermediate reaction product; and iii) contacting the second intermediate reaction product with a halogen-containing Ti-compound, a monoester as activating agent, a 1,3-diether as an internal electron donor, and optionally a diester as an additional internal electron donor.

The present invention relates to a process for preparing a catalyst component for polymerization of an olefin comprising the steps of: i) contacting a compound R.sup.9.sub.zMgX.sub.2-z wherein R.sup.9 is aromatic, aliphatic or cyclo-aliphatic group containing up to 20 carbon atoms, X is a halide, and z is in a range of larger than 0 and smaller than 2, with an alkoxy- or aryloxy-containing silane compound to given a first intermediate reaction product; ii) contacting the first intermediate reaction product with at least one activating compound selected from the group formed by electron donors and compounds of formula M(OR.sup.10).sub.v-w(OR.sup.11).sub.w, wherein M can be Ti, Zr, Hf, Al or Si, and M(OR.sup.10).sub.v-w(R.sup.11).sub.w, wherein M is Si, each R.sup.10 and R.sup.11, independently, represent an alkyl, alkenyl or aryl group, v is the valency of M, v being either 3 or 4, and w is smaller than v, to give a second intermediate reaction product; and iii) contacting the second intermediate reaction product with a halogen-containing Ti-compound, a monoester as activating agent, a 1,3-diether as an internal electron donor, and optionally a diester as an additional internal electron donor.

Compounds of formula (I): where R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b, R.sup.5, R.sup.6 and R.sup.7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof. ##STR00001##

Compounds of formula (I): where R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b, R.sup.5, R.sup.6 and R.sup.7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof. ##STR00001##

Disclosed herein are 1,4-naphthoquinone analogs, pharmaceutical compositions that include one or more of such 1,4-naphthoquinone analogs, and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as prostate cancer with such 1,4-naphthoquinone analogs. Also included are combination therapies wherein a 1,4-naphthoquinone analog disclosed herein, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.

Disclosed herein are 1,4-naphthoquinone analogs, pharmaceutical compositions that include one or more of such 1,4-naphthoquinone analogs, and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as prostate cancer with such 1,4-naphthoquinone analogs. Also included are combination therapies wherein a 1,4-naphthoquinone analog disclosed herein, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.

Shown is a compound represented by formula (1). For example, R.sup.1 is alkyl having 1 to 15 carbons; MES is a mesogen group having at least one ring; Sp.sup.1 is a single bond or alkylene having 1 to 10 carbons; M.sup.1 is methyl; and R.sup.2, M.sup.2 and M.sup.3 are hydrogen.

##STR00001##

Compounds of formula (II):

##STR00001##

wherein

##STR00002##

R.sup.1, R.sup.2, R.sup.5 and R.sup.13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

Compounds of formula (II):

##STR00001##

wherein

##STR00002##

R.sup.1, R.sup.2, R.sup.5 and R.sup.13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

Compounds represented by Formula I:

##STR00001##

wherein A, B, W, V, Z, Ra, Rb, n and m are as defined in the instant specification, or by Formula Ia, Ib, III, IV or V, as defined in the instant specification, and uses thereof in modulating an activity of a voltage-dependent potassium channel and/or a TRPV1 channel and in treating a medical condition associated with an activity of these channels, such as medical conditions associated with neuronal hyper-excitability, are provided.